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Abstract
Amyloid-β proteins (Aβ) of 42 (Aβ42) and 40 aa (Aβ40) accumulate as senile plaques (SP) and 
cerebrovascular amyloid protein deposits that are defining diagnostic features of Alzheimer’s 
disease (AD). A number of rare mutations linked to familial AD (FAD) on the Aβ precursor 
protein (APP), Presenilin-1 (PS1), Presenilin-2 (PS2), Adamalysin10, and other genetic risk 
factors for sporadic AD such as the ε4 allele of Apolipoprotein E (ApoE-ε4) foster the 
accumulation of Aβ and also induce the entire spectrum of pathology associated with the disease. 
Aβ accumulation is therefore a key pathological event and a prime target for the prevention and 
treatment of AD. APP is sequentially processed by β-site APP cleaving enzyme (BACE1) and γ-
secretase, a multisubunit PS1/PS2-containing integral membrane protease, to generate Aβ. 
Although Aβ accumulates in all forms of AD, the only pathways known to be affected in FAD 
increase Aβ production by APP gene duplication or via base substitutions on APP and γ-secretase 
subunits PS1 and PS2 that either specifically increase the yield of the longer Aβ42 or both Aβ40 
and Aβ42. However, the vast majority of AD patients accumulate Aβ without these known 
mutations. This led to proposals that impairment of Aβ degradation or clearance may play a key 
role in AD pathogenesis. Several candidate enzymes, including Insulin-degrading enzyme (IDE), 
Neprilysin (NEP), Endothelin-converting enzyme (ECE), Angiotensin converting enzyme (ACE), 
Plasmin, and Matrix metalloproteinases (MMPs) have been identified and some have even been 
successfully evaluated in animal models. Several studies also have demonstrated the capacity of γ-
secretase inhibitors to paradoxically increase the yield of Aβ and we have recently established that 
the mechanism is by skirting Aβ degradation. This review outlines major cellular pathways of Aβ 
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degradation to provide a basis for future efforts to fully characterize the panel of pathways 
responsible for Aβ turnover.
Keywords
Alzheimer’s disease; amyloid β degradation; amyloid β peptide; endothelin-converting enzyme; 
insulin-degrading enzyme; neprilysin; neurodegeneration
1. INTRODUCTION
AD is the most common form of dementia in the elderly population in the United States, 
with age being the number one risk factor but the occurrence of a number of cognitively 
normal centenarians argues against the aging process directly causing dementia. It has been 
reported that over 50% of people who are 85 years or older suffer from the disease [1]. 
Unfortunately, all FDA approved treatments for AD only provide temporary cognitive 
improvement with negligible disease modifying effect on the neuropathology [2, 3]. Since 
sporadic AD generally manifests late in life, multiple environmental, physiological and 
cellular processes appear to modify the risk for developing the disease [4]. It may be 
possible to target one or more of these hits to prevent the disease, but the repeated failure of 
clinical trials suggests that treatment treatments devised so far are missing key therapeutic 
targets. Therefore, it is important to understand the silent biochemical cascades involved in 
neurodegeneration, hoping that these will walk us toward the disease etiology. The reality in 
the AD field is that yet we have no clue as to its cause, “an embarrassment of riches” where 
all bets are on, from hormonal deficiencies to viral reactivation [5].
As a central component of life, the levels and types of proteins are important in determining 
the structure of cells and in optimizing their role within the context of their function. In 
addition to controlling gene expression at the transcriptional and translational levels, the 
steady state concentration of a particular protein within a cell is also determined by its 
turnover rate. A plethora of studies have demonstrated that regulation of proteolysis play a 
key role in many processes critical to cell survival. Such mechanisms are also central to 
many physiologic pathways in multicellular organisms such as blood clotting, complement 
activation, cell cycle, cell differentiation and embryo growth pattern and development. 
Specific proteins are called into action at defined times during development and are 
subsequently degraded after completing their task. Failure of these processes is associated 
with substantive congenital morbidity and mortality. At the other end of life, these processes 
can significantly contribute to age related disease. While some structural proteins remain 
stable for prolonged periods, others with regulatory function are constantly degraded; i.e., 
cleaved to either activate or inactivate precursors [6]. If, however, the proteins are not 
degraded, then their subsequent accumulation can significantly affect their regulatory 
activity to ultimately cause dysfunction. Cellular homeostasis must therefore be maintained 
by turnover mechanisms to ensure a fastidious balance. This is also the case with clearance 
of Aβ from cells in the normal brain and in AD patients. Here in, this review highlights the 
predominant cellular mechanisms that have been demonstrated to affect the trafficking and 
clearance of the Aβ peptide within the brain.
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AD is characterized by widespread neuronal degeneration and synaptic loss affecting the 
hippocampus, cortex and other brain regions, resulting in diffuse brain atrophy. However, 
senile plaques (SP) and neurofibrillary tangles (NFT), the two microscopic hallmark lesions 
originally described by Alois Alzheimer, are still considered the most important pathological 
markers of AD [7]. SPs are primarily composed of Aβ and NFTS of hyperphosphorylated 
microtubule-associated protein tau (MAPT) accumulates in the form of paired helical 
filaments. Whether Aβ accumulation or hyperphosphorylated tau contribute to the disease 
pathogenesis or are merely bystander markers of the disorder, remains a matter of intense 
debate [8–12]. Nevertheless, Aβ accumulation is found in all forms of the disease and its 
production is specifically altered by FAD mutations even in cultured cells The convergence 
of FAD mutations on APP and presenilins to specifically increase Aβ, which then 
accumulates as SPs, lays the foundation for the widely recognized ‘amyloid hypothesis’ of 
AD [13]. This hypothesis proposes that abnormally high levels of Aβ trigger a cascade of 
events leading to neurodegeneration. The hypothesis is supported by four main observations: 
i)-amyloid accumulation generally precedes the development of MAPT abnormalities by 
many years [14, 15], ii)-mutations in the APP gene cause a form of familial AD that is 
neuropathologically indistinguishable from the sporadic form [16]; iii)- Aβ oligomers are 
neurotoxic [17–19] and iv) APP variants that reduce Aβ production protect against AD 
pathogenesis and increase longevity [20]. Thus, understanding the regulation of Aβ 
production and turnover is critical to identify potential therapeutic targets [20–24].
2. AMYLOID PRODUCTION PATHWAYS
Aβ is produced following sequential cleavage ofa larger precursor protein, APP, which has 
become the major subject of study in AD pathogenesis. APP is a large type-I integral 
membrane protein of 695–770 aa that is sequentially processed by either BACE1 or α-
secretase to carboxy-terminal fragments of 99 aa (CTFβ) or 83 aa (CTFα). An 
intramembrane protease, γ-secretase, cleaves CTFβ to 4 kDa Aβ and CTFα to a smaller 3 
kDa fragment named P3 or Aα (Fig. 1). Other Aβ-like fragments have also been described, 
but they are relatively minor [25]. Several reviews, have detailed the processing pathway of 
APP [13]. The compartmentalization of the processing events is a critical part of its 
regulation [26]. In particular, this report demonstrated that BACE1 and α-secretase 
processing takes place in two different cellular compartments. Although BACE1 represents a 
minor pathway for APP processing, the enzyme is not limiting and overexpression of APP 
results in a proportionately higher CTFβ and Aβ yield. Finally inhibiting α-secretase does 
not increase Aβ production, showing that although it cleaves inside the Aβ sequence and 
represents the major APP processing pathway, it does not limit Aβ biogenesis [26]. The 
exact compartments involved in this process vary by cell type as Aβ is generated in both 
constitutive and regulated secretory pathways [27, 28]. It is generally accepted that APP is 
first transported to the cell surface and processed either in the secretory pathway or at the 
surface by a constitutive or inducible form of α-secretase to CTFα [29–32]. The membrane-
bound CTFα fragment is processed by γ-secretase which appears to reside within multiple 
locations including the Golgi apparatus and the cell surface [33]. APP not processed by α-
secretase becomes internalized into endocytic vesicles, where BACE1, an aspartyl protease 
with an acid pH optimum, cleaves it to generate CTFβ. This, in turn, is further processed by 
Baranello et al. Page 3
Curr Alzheimer Res. Author manuscript; available in PMC 2016 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
γ-secretase to Aβ40 and Aβ42 that gets transported to the cell surface and secreted via 
recycling vesicles (Fig. 1, 2). It has been proposed that accumulated Aβ generates oligomers 
that interact with phosphorylated MAPT to induce synaptic dysfunction [34]. In addition to 
genetics, epigenetics, and environment, other factors including dietary imbalance, exercise, 
and early-life exposure to metals and pesticides (as described in the ‘LEARn’ model) also 
play an important and complex role in the development of dementia[35, 36].
3. GENE VARIANTS LINK Aβ TO AD
Although FAD only accounts for a small fraction of AD cases (~5%), these mutations on 
APP, PS1 and PS2induce the entire range of pathology starting with increase in Aβ 
accumulation to SPs, passing through NFT formation and leading to synaptic dysfunction, 
neuron loss, brain atrophy and dementia [9, 37, 38]. Despite the strong genetic and toxic 
connection between Aβ and AD, the topic remains controversial with some investigators 
dismissing its role as an epiphenomenon [39]. Most of the argument revolves around a direct 
role for Aβ toxicity in the AD-associated neurodegeneration as a potential treatment target. 
Indeed, with failure of clinical trials against Aβ, these arguments have suddenly become 
quite popular. However, in vivo labeling for Aβ provided evidence that these lesions 
accumulate as early as twenty years before the onset of dementia and highlight the multistep 
process of dementia with Aβ serving as a potential preclinical target, like cholesterol for 
cardiovascular disease [40–43]. These imaging studies have led to a new hypothesis that SPs 
and even NFTs are early preclinical stages of the disease and that even some visible 
neurodegeneration predates the onset of mild dementia, suggesting that treatments to reduce 
Aβ and MAPT must start early during the disease course for subjects at high risk for 
prevention of dementia [42, 43]. The prevention focus has become widely recognized and 
discussed [44]. These studies highlight the importance of understanding the basic 
mechanisms underpinning the development of dementia, and the various steps down the 
slippery steps that may need reinforcement for preventive strategies. The most revealing 
strategies have been imaging to define the disease, genetics to identify minor variants of the 
genome that undergo linkage disequilibrium, and genomic and proteomic strategies to 
identify changes in the disease. The three major FAD mutations have been followed by 
extensive efforts at identifying loci linked to AD and other neurodegenerative diseases, and 
have identified a large crop of genes associated with various diseases. They also show that 
several gene variants may be associated independently with multiple degenerative diseases. 
Interestingly, while APP, PS1 and PS2 are all linked to Aβ production, few variants are 
consistently linked to Aβ degradation. However, we have recently discovered that 
impairment of γ-secretase can paradoxically increase Aβ yield by skirting Aβ degrading 
pathways [45]. We hence need to determine whether mutations in PS1 and APP that 
presumably impair γ-secretase activity [13] can also operate via this mechanism. 
Interestingly, proteomic strategies have revealed that there are several proteins that 
accumulate in AD along with Aβ and MAPT, indicating that the disease represents failure of 
protein homeostasis [46].
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4. APOE AND SELECTED RISK FACTORS AFFECTING AMYLOIDOSIS
Since the start of the Human Genome Project, there have been a number of GWAS studies 
that have identified several genetic risk factors associated with AD [37]. A major AD risk 
factor identified by genome wide association studies is ApoE-ε4, which is strongly 
associated with typical late onset forms of AD, but with low penetrance [47–49]. ApoE 
within the brain is produced by glial cells [50], and normally maintains brain cholesterol and 
triglyceride homeostasis, and in the periphery and has been linked to familial 
hypercholesterolemia syndromes. ApoE is additionally the major cholesterol transporter 
within the brain and appears to drive AD by multiple mechanisms that, as discussed below, 
includes reduced Aβ degradation [47, 51]. ApoE exists as a combination of three different 
isoforms, ε2, ε3, and ε4, wherein ε4 increases AD risk in a dose-dependent manner and ε2 
provides some protection against the disease risk introduced by presence of an ε4 allele [52]. 
Brain imaging studies utilizing the Pittsburgh compound B show that in comparison to 
ApoE4-ε4-negative subjects, cognitively normal middle-aged subjects carrying the ApoE-ε4 
allele have a far greater likelihood of having a higher cerebral amyloid load [43, 53] and, 
consequently, lower levels of cerebrospinal fluid (CSF) Aβ42 [53]. Studies show that ApoE-
ε4, which also promotes premature atherosclerosis, is significantly less frequent in 
centenarians than in controls, whereas the ApoE-ε2 allele that has been associated with type 
III and IV hyperlipidemia is significantly increased in this extremely long-lived group [54]. 
However, ApoE-ε4 as a risk factor in human disease is complex, as it appears to protect 
carriers against development of age-related macular degeneration, a condition that is 
associated with amyloid deposition in subretinal pigmented epithelium deposits known as 
drusen [55]. Several theories are built around ApoE-ε4, such as the failure of CNS 
cholesterol homeostasis, promoting plaque formation by chaperoning Aβ deposition, 
reduced Aβ degrading capacity, incorporation into plaques as fragments, promoting APP 
degradation affecting neuronal survival to ultimately cause AD-related neurodegeneration 
[56–58]. There is also evidence that ApoE facilitates aggregation and polymerization of Aβ 
into amyloid fibrils, a process that is less efficiently carried out by the ApoE-ε4 allele [59–
63].
Cholesterol is an independent AD risk factor and can foster amyloidosis by stimulation 
BACE1 processing of APP[64]. Thus cholesterol transport may be another mechanism for 
ApoE-driven amyloidosis [47]. It is interesting that HMGCR, a cholesterol synthesis gene, 
has variants that act as genetic modifiers that reduce AD risk of ApoE-ε4 [48]. In addition to 
cholesterol, HMGCR also mediates synthesis of isoprenoids that regulate several small 
GTPases such as rho and ras, and these, in turn, regulate Aβ biogenesis [65]. It is reported 
that ApoE receptors, LRP, and α2-macroglobulin, are involved in the internalization of APP 
and Aβ generation, and degradation [66, 67], because ApoE binds Aβ and APP [68, 69]. 
Once internalized and associated with the recycling pathways, ApoE-ε3 more efficiently 
promotes Aβ lysosomal trafficking and degradation than does ApoE-ε4 [60]. These data 
point to rapid endocytic trafficking of Aβ-containing vesicles in the presence of ApoE 
resulting from an increase in efficiency of the recycling of Rab7 from lysosomes to early 
endosomes. Thus, ApoE-induced intracellular Aβ degradation appears to be mediated by the 
cholesterol efflux function of ApoE, which lowers cellular cholesterol levels and 
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simultaneously facilitates the intracellular trafficking of Aβ to lysosomes for degradation 
[63]. It is, however, important to note that the degradation pathway for Aβ in lysosomes has 
not yet been worked out. In fact, our laboratory found that inhibition of the aspartyl-, serine- 
and thiol- protease pathways was not sufficient to efficiently block Aβ degradation in 
lysosomes, suggesting that other novel pathways may be involved in its turnover.
5. CELLULAR MAINTENANCE AND Aβ REGULATION
The role of Aβ degradation takes on a new importance based on our group’s recent findings 
that Aβ production and degradation may be coupled. Specifically, partial inhibition of γ-
secretase, the final step in Aβ production, paradoxically increases Aβ production by 
circumventing one or more Aβ degradation pathways [45]. However, only a few of the 
multiple redundant pathways that degrade Aβ have been carefully studied [70–72]. The 
purpose of this review is to highlight the known and proposed Aβ degrading pathways to 
provide a foundation for further research in this important area. Two of the major pathways 
that mediate cellular proteolysis involve the proteasome and the lysosome. The two systems 
maintain cellular homeostasis by digesting multiple classes of proteins, including faulty or 
misfolded proteins with different lifespans, and play an important role in orchestrating 
protein concentrations inside the cell [73–75]. Other widely recognized pathways are 
cytosolic neutral proteolytic pathways linked to cellular injury and programmed death. In the 
first pathway, a family of Ca++-activated cysteine proteases named calpains is induced 
during cellular injury. Secondly, another group of cystolic cysteine-dependent aspartate-
directed proteases (caspases) are activated by rapid posttranslational mechanisms and trigger 
a cascade of events that are characteristic of programmed cell death or apoptosis [76]. The 
role of these pathways in Aβ turnover is beginning to be uncovered, as described below.
5.1. Ubiquitin-Proteasome System (UPS) has Function in SP and NFT Formation
The proteasome is a constitutive multi-catalytic, multi-subunit protease complex that utilizes 
homopolymers of ubiquitin as a signal to target proteins for degradation in an ATP-
dependent pathway[71, 77–79]. In mammals, the most common form is the 26S proteasome 
(~2 million Da) containing a proteolytic 20S core subunit flanked by two 19S regulatory 
subunits. The protease complex core is hollow, which provides an opening for proteins to 
enter and become degraded. First, ubiquitin is adenylylated by the E1 ubiquitin-activating 
enzyme and subsequently transferred to the active-site cysteine of the ubiquitin-conjugating 
enzyme - E2. In the final step, a family of ubiquitin ligases - E3 -identifies specific targets 
and catalyzes the transfer of ubiquitin from E2 to the target protein [80]. A target protein 
must be labeled by at least 4 ubiquitin molecules before it becomes recognized for 
proteolysis. Although Aβ is not directed ubiquitinated other proteins involved in its 
degradation participate in this pathway. NFT’s are also heavily ubiquitinated [81]. The rate 
of turnover of an individual protein is determined by the amino acid at its N-terminus -
termed the ‘N-end’ rule [79, 82, 83]. Although cytoplasmic and nuclear proteins are primary 
targets of proteasome-mediated degradation, there are other proteins in the endoplasmic 
reticulum (ER) and the secretory pathway that can also be degraded [84]. Unfolded proteins 
that translocate to the ER can be degraded by ER-associated degradation (ERAD), which 
acts as a quality control system and is an essential component of the secretory pathway that 
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tags ER proteins for degradation. ERAD substrates are ultimately transported to the cytosol 
where they can be more easily accessed by the proteasome [85]. Interestingly, proteins that 
escape degradation and accumulate in the cytosol can form an aggresome, a juxtanuclear 
inclusion body that remains accessible for removal by autophagy or proteasome-dependent 
degradation [86, 87]. However, since our understanding of aggresome formation in 
neurodegenerative diseases is limited, additional studies are required to advance our 
knowledge of its underlying molecular mechanisms.
A number of studies have implicated impairment of UPS and proteasome-dependent 
degradation in neurodegenerative disorders such as AD and Parkinson’s disease (PD). The 
role of the proteasome in AD has been previously reviewed and is therefore outside the 
scope of this article [88]. UPS dysfunction leads to the accumulation of polyubiquitinated 
proteins, as seen in several neurodegenerative disorders such as AD, PD and Huntington’s 
disease (HD) [89]. Ubiquitin immunohistochemistry detects conjugates in NFTs, dystrophic 
neurites in SPs, lysosomes, endosomes, and a variety of inclusion bodies and degenerative 
fibers making it a nearly universal label in protein accumulation diseases [90, 91]. In AD, it 
appears that the ubiquitin-related pathways are involved in the development of abnormal 
neuritic processes and NFTs rather than Aβ accumulation [81, 92]. Pharmacological 
inhibition of the proteasome is sufficient to induce neurodegeneration and cell death [93–
95], demonstrating its importance in cellular homeostasis. It has been reported that 
proteasome inhibition increases APP processing at the γ-secretase site and elevates levels of 
Aβ in a human neuroblastoma - SH-SY5Y - cell line [83, 96]. Furthermore, it has been 
demonstrated that Aβ and MAPT inhibit proteasome activity [97, 98]. However, despite the 
ability of Aβ40 to inhibit the proteasome, it does not appear to be a substrate of the UPS 
[98]. The proteasome can additionally modulate intracellular concentrations of both PS1 and 
PS2, which may indirectly affect γ-secretase activity [99], and provides insights into the 
complexity of the regulatory system that encompasses the proteasome and key elements of 
Aβ generation and clearance.
Despite the evidence that implicates impaired UPS function with AD, we are still uncertain 
about its exact role in aging and neurodegeneration. Even though the proteasome plays a 
major part in regulating the concentration of proteins while degrading excess or damaged 
proteins via proteolysis, if the neuron’s metabolic activity becomes compromised and the 
UPS activity declines, the cell must compensate with redundant pathways to survive. In 
particular, the role of UPS function in Aβ degradation to prevent its accumulation in the 
disease state remains to be investigated.
5.2. Lysosomal Processing and its Role in Regulating AD-Associated Proteins
Most extracellular and some cell surface proteins can be internalized via receptor-mediated 
endocytosis and degraded within lysosomes. These organelles contain acid proteases (such 
as cathepsins B, H, L, and D) and acid hydrolases (such as phosphatases, nucleases, 
proteases, and glycosidases). Material tagged for degradation is first surrounded by a 
phagophore-formation and then wrapped into double membrane vesicles called 
autophagosomes, which then can fuse with late endosomes to form an amphisome. Some 
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cytosolic proteins are degraded after being engulfed in autophagic vacuoles that fuse with 
lysosomes for removal [100–103].
Previous reports have shown that endosomes and autophagic vacuoles accumulate in the 
brains of both AD patients and APP-transgenic mice, and that they co-localize intimately 
with the γ-secretase complex, APP, and CTFβ [104]. Other studies also observe the 
accumulation of endosomes and present evidence to indicate that it may be a consequence of 
impaired lysosomal proteolysis [102]. These data suggest that endosomes maybe one of the 
generation sites for Aβ as inhibiting the C-subunit of vacuolar-type H+-ATPase with 
bafilomycin, a macrolide antibiotic that inhibits vesicular acidification, leads to intracellular 
accumulation of both APP and CTFs within the cell [105–108]. This may be due to the 
processing of APP to CTFβ by BACE1, an aspartyl protease with an acid pH optimum, in an 
endosome where γ-secretase is also present and converts CTFβ to Aβ [25, 45]. As inhibition 
of lysosomal acidification will inhibit Aβ production and, thereby, prevent us from 
evaluating its degradation, one cannot use this approach to determine whether freshly 
released Aβ is also degraded in the endosome by multiple proteases to limit its yield in the 
medium.
Impaired autophagic processes have been described to significantly reduce extracellular Aβ 
due to the inhibition of Aβ secretion through impaired exocytosis [109]. However, this 
impairment does not inhibit Aβ that, instead, accumulates within intracellular vesicles. 
Moreover, autophagy deficiency-induced neurodegeneration is further aggravated by 
amyloidosis. These, together, have been reported to severely impair memory in an AD 
mouse model. It has been reported that autophagy directly affects the levels of both 
intracellular and extracellular Aβ, and that intracellular Aβ severely affects memory 
function. This bolsters the hypothesis that intracellular Aβ is more pathogenic than soluble 
Aβ in AD [110–113]. Briefly, loss of Atg7 reduces Aβ yield, as evaluated by ELISA 
analysis, while immunohistochemistry detected an accumulation of intracellular Aβ.
During the early stages of AD, it has been reported that neurons in vulnerable brain regions, 
such as the entorhinal cortex and hippocampus, respond by increasing their production of 
lysosomal system components [60]. Aging results in the increased expression and lysosomal 
localization of aspartyl proteases in cortical and brainstem neurons and changes in the 
endosomal-lysosomal pathway, which may be related to altered intracellular APP 
metabolism [114, 115]. It has been reported that much of the γ-secretase activity occurs 
within the endosome to produce nascent Aβ [116]. An overexpression of Rab5 or Rab7, 
small GTPases that function in vesicle fusion for early and late endosomes, respectively, 
significantly accelerates Aβ endocytic trafficking to the lysosomes [117]. A potential role for 
Rho-GTPase has also been elucidated in TgCRND8, a transgenic mouse model that rapidly 
deposits human Aβ [118]. However, as this compartment is known to be rich in other acid 
proteases, nascent Aβ may also undergo degradation at this location. As described later, at 
least one protease, endothelin-converting enzyme has been implicated in Aβ degradation 
within this compartment [70, 119]. In addition, cathepsin B has been associated with Aβ 
degradation and its loss in knockout mice leads to an increase in Aβ and development of 
neurodegeneration [120–122]. However, others have suggested that cathepsin B is a β-site 
cleaving enzyme specific for wild type APP in the regulated secretory pathway [123, 124].
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6. OTHER PATHWAYS FOR Aβ TURNOVER
In addition to the major protein elimination pathways - proteasomal and lysosomal 
degradation, cells employ a number of constitutive and regulated proteolytic activities that 
maintain proteostasis - the integrated pathways that regulate the biogenesis, trafficking, and 
degradation of proteins to maintain their steady-state levels [125]. There is increasing 
evidence that deficient clearance rather than increased production of Aβ contributes to its 
accumulation in late-onset AD [126]. Aside from the typical deposition into blood and CSF, 
it has also been reported that Aβ deposits along perivascular interstitial fluid drainage 
channels [127] possibly leading to cervical lymph nodes or other lymphatic pathways (Fig. 
2). Consistently, recent reports indicate that Aβ is present in lymph nodes and accumulates 
with brain amyloid deposition [128]. Lymphatic clearance of Aβ appears to be an 
overlooked, nevertheless important pathway for Aβ removal, particular in view of the recent 
GWA studies highlighting the role of several genes involved in trafficking between the brain 
and lymph nodes. Some of these genes code for protein receptors localizing to brain immune 
competent cells such as dendritic and microglial cells. Germane to this discussion, these 
cells participate in Aβ degradation and clearance. Although only a few proteolytic pathways 
have been implicated in the degradation of Aβ, there are several enzymes possessing a broad 
specificity that may be degrade Aβ; but the exact identity and role of these enzymes in 
maintaining Aβ levels needs further investigation [129].
6.1. Insulin-Degrading Enzyme (IDE)
Insulin-degrading enzyme is a zinc-endopeptidase located in the cytosol, peroxisomes, and 
at the cell surface that can cleave a variety of small peptides. These include insulin, 
glucagon, and insulin-like growth factors I and II, and IDE also converts β-endorphin to γ-
endorphin [130, 131]. Interestingly, the enzyme does not contain an obvious signal sequence 
and is mostly intracellular, yet reports suggest that IDE, in neurons, may be membrane-
associated and even secreted into the medium [132, 133]. However, it remains unclear 
whether IDE is secreted or simply released from damaged cells. IDE appears to participate 
in both insulin and Aβ catabolism and its levels are reported to be increased in the 
hippocampus of AD patients [134]. However, the extent to which IDE mediates these 
processes in vivo has been questioned as the protein is predominantly cytoplasmic and lacks 
a signal sequence [59]. When the IDE gene was selectively deleted in a hybrid transgenic 
mouse, it presented key hallmark phenotypic characteristics of AD, including a chronic 
elevation of cerebral Aβ. The IDE knock-out animals showed a significant 64% increase in 
brain levels of Aβ X-40 over their wild type littermates [135, 136]. Using Western blotting 
and in-situ hybridization, it was reported that there was an inverse relationship between IDE 
expression and age, suggesting that loss of this activity may play a role in the development 
of AD pathology [137].
Although it is predominantly a cytosolic protease, IDE activity is detected in the medium 
where it can also degrade secreted Aβ [138]. It has been reported to be the primary soluble 
Aβ degrading enzyme at neutral pH within the human brain [139]. In a study where chinese 
hamster ovary cells transfected with APP were treated with conditioned medium of BV-2 
microglial cells expressing IDE, there were decreased levels of monomeric, but not 
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oligomeric, Aβ40 and Aβ42 secreted into the medium [140]. Interestingly, Aβ40 and Aβ42 
regulate IDE levels via a feedback mechanism, suggesting that cells may attempt to regulate 
IDE expression to eliminate these toxic peptides [141]. Studies within our laboratory have 
provided evidence that CTFγ is, likewise, degraded by IDE in a dose-dependent manner and 
at multiple cleavage sites, which is consistent with its role in the removal of multiple APP-
derived γ-secretase cleavage products [136, 142]. A careful analysis of its in vivo function is 
essential to determine the true contribution of IDE in Aβ accumulation and AD-associated 
neurodegeneration. It is also important to understand the mechanisms by which IDE is 
released into the extracellular space where it can degrade Aβ.
6.2. Neprilysin (NEP)
Neprilysin (a.k.a. neutral endopeptidase 24.11 or enkephalinase) is a membrane-bound zinc 
endopeptidase that is synthesized in the Golgi and transported to the cell surface where its 
ectodomain is shed into the extracellular space. Although there are four splice variants of the 
24 exon NEP gene, their protein-coding region remains constant and codes for a single 750 
aa polypeptide (NCBI Accn # NP_009220). Analysis of the NEP sequence by PSORT [143] 
reveals a type 2 integral-membrane protein structure that starts with a short 31 aa 
cytoplasmic domain and has a single transmembrane domain (residues 31–47) that serves as 
a signal and anchor followed by a long extracellular domain that constitutes its catalytically 
active domain. Some known substrates of the enzyme are shown in Table 1. NEP is a part of 
a group of vasoendopeptidases that include endothelin-converting enzyme and angiotensin 
converting enzyme, which are key drug targets for the control of hypertension. NEP is 
expressed in several tissues, most notably the brain, but is also abundant within the kidney 
and the lung. NEP is a neutral metalloendopeptidase that is inhibited by phosphoramidon, a 
natural compound derived from Streptomyces tanashiensis, and thiorphan, an active 
metabolite of Rececadotril, an anti-diarrheal agent. In a pioneering study, Iwata et al. (2000) 
evaluated the catabolism of injected radiolabeled synthetic Aβ in the rat hippocampus and 
discovered that the yield of residual peptide increased significantly in the presence of 
thiorphan, an inhibitor of NEP [144]. In accord with this, NEP gene disruption showed a 
gene dose-dependent elevation of endogenous levels of Aβ in the mouse brain [145]. These 
data suggest that dysregulation of NEP activity may have profound effects on AD 
pathogenesis and progression by promoting Aβ deposition. The role of NEP in AD is further 
supported by a decline in NEP in the AD brain, particularly in vulnerable regions such as the 
hippocampus and the midtemporal gyrus [146], associated with an increase in deposition of 
Aβ [147]. However, in the striatum, a brain region where Aβ does not typically accumulate, 
NEP levels appear to increase with age [148]. Interestingly, NEP levels appear to be reduced 
in the brain of cerebral amyloid angiopathy subjects but are increased in the AD brain [149, 
150]. Presynaptic NEP has also been demonstrated to degrade Aβ efficiently and to retard 
development of amyloid pathology [151]. Further, amyloid plaques have been described that 
were co-localized with reactive astrocytes expressing high levels of NEP [151]. NEP is 
therefore a promising candidate protease that accounts for the degradation of secreted Aβ, 
and mechanisms that maintain its activity in the aging brain are important to investigate. 
However, as the size of the catalytic subunit of the enzyme is estimated to be smaller than an 
Aβ monomer, an important area of inquiry that requires more detailed examination relates to 
the mechanisms by which the enzyme accommodates this large substrate [152]. The role of 
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Neprilysin-2, a soluble and secreted endopeptidase related to NEP, is another unexplored 
area in the field.
6.3. Endothelin-Converting Enzyme (ECE)
Like NEP, endothelin-converting enzyme is a member of the M13 family of zinc-
metalloproteases that processes the inactive big endothelin to its active mature form and, 
thereby, regulates blood flow [153]. The primary substrates (Table 1) for ECE are big 
endothelin-1 and -2, which are potent vasoconstrictive peptides produced in vascular 
endothelial cells. There are two forms of ECE, each having multiple isoforms generated by 
multiple promoters. ECE-1 is of particular interest, as its isoforms are differentially located 
at the cell surface and within different intracellular compartments, including endosomes 
[154]. A homologous enzyme ECE-2 and its isoforms also show similar activities but their 
localization appears to be exclusively intracellular, including endosomes and the role of its 
differentially spliced isoforms is not yet established. ECE-1 has four human isoforms (735–
770 aa), which are all encoded by a single gene on chromosome 1 (1p36). Each isoform has 
a unique N-terminal cytoplasmic domain that determines their subcellular localization along 
with a shared transmembrane domain (Fig. 3). ECE-1 preferentially cleaves at the N-
terminal side of its hydrophobic substrates, corresponding to residues Leu17, Val18, and 
Phe20 of the Aβ peptide [119]. Although NEP and ECE share a similar primary structure, 
significant differences exist between the two. ECE-1 is a disulfide-linked dimer, whereas 
NEP is a monomer. As opposed to NEP, ECE-1 is relatively insensitive to thiorphan, but is 
inhibited by phosphoramidon. A recent study examining the cellular distribution of the ET 
system in the brain showed the immunohistochemical evidence for the presence of virtually 
all components of the ET system in 24 regions of the human CNS, including neurons within 
the cingulate gyrus, hypothalamus, caudate, cerebellum, amygdala, and hippocampus [155]. 
Therefore, ECE appears to be present within a number of key regions of the brain; thereby, 
suggesting that this enzyme may be important in AD pathogenesis.
ECE-1 is the best characterized Aβ degrading enzyme, as its activity has been demonstrated 
in cell cultures and animal models [70]. Interestingly, although they were considered as 
neutral endopeptidases, the pH optimum of ECE was shown to be substrate dependent with 
preferential cleavage of Aβ at acid pH, cleaving both Aβ40 and Aβ42 with a strong 
preference for the former [119]. This finding is consistent with the intracellular degradation 
of Aβ by ECE-1, which strongly affects the yield of Aβ production, but does not affect the 
degradation of externally added Aβ into the medium. Moreover, genetic knock down of 
either ECE-1 or ECE-2 in mice has been reported to significantly increase both Aβ40 and 
Aβ42 levels, whereas levels of APP and CTFs remained unchanged [156]. These studies 
further demonstrate the importance of NEP in Aβ degradation in vivo, as knocking down 
both enzymes increases Aβ levels more than either enzyme alone. Additionally, genetically 
knocking out both NEP and ECE yields an additive increase in Aβ within the brain of mice, 
suggesting that the two enzymes are responsible for regulating two different pools of Aβ. 
However, it has been reported that there was no change in the levels of ECE-1 in post-
mortem AD brain compared to cognitively normal control brain specimens [157], and a 
reduction in ECE-2 (Table 1), suggesting that the activity is not subject to feedback 
regulation by Aβ accumulation [158]. This finding is also consistent with the coupled 
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production and degradation of Aβ in the recycling endosome with residual Aβ either being 
transported to the surface for secretion from the cell or to lysosomes for further degradation.
6.4. Angiotensin Converting Enzyme (ACE)
Angiotensin-converting enzyme (aka dipeptidyl carboxypeptidase-1 or DCP-1) is a 
membrane-bound ectoenzyme that plays an important role in blood pressure and body fluid 
homeostasis by catalyzing the conversion of angiotensin I to angiotensin II, and degrading 
bradykinin (Table 1), which is a potent vasodilator. Therefore, ACE inhibition has become 
an effective treatment strategy for hypertension. ACE is secreted in the lung and kidney by 
cells in the inner layer of blood vessels. Studies on the renin-activating system of 
mammalian brains may elucidate potential associations between ACE and AD. It has been 
reported that angiotensin in astrocytes is required for the functional maintenance of the 
blood-brain barrier [159], which is also impaired in AD. Additionally, ACE inhibits Aβ 
toxicity in cultured PC12 cells, blocks the aggregation of synthetic Aβ, and cleaves Aβ 
between the Asp7-Ser8 residues [160, 161].
Although such studies are helpful in elucidating ACE’s activity in relationship to AD, there 
are data that suggest that ACE is not a direct physiological regulator of steady-state Aβ 
concentrations in the brain [162]. Following ACE inhibition or genetic disruption, Aβ levels 
remain unchanged in both soluble and insoluble fractions in vivo[156]. Therefore, despite 
ACE’s ability to cleave Aβ in vitro, in vivo studies indicate that it does not appear to regulate 
cerebral amyloidosis. Intriguingly, the level/activity of the enzyme, itself, appears to be 
increased in AD brains [163–165].
6.5. Plasmin
The serine protease plasmin is derived from the inactive zymogen plasminogen following 
cleavage by plasminogen activators, such as tissue plasminogen activator and urokinase 
plasminogen activator. Plasmin is involved in the degradation of blood plasma proteins, 
including fibrin and many components of the extracellular matrix. Studies have successfully 
demonstrated that plasmin degrades both non-aggregated monomeric and aggregated 
fibrillar Aβ with physiologically relevant efficiency [166]. There is evidence indicating that 
plasmin activity is reduced in AD human brain homogenates compared to cognitively 
normal control subjects. However, plasminogen and plasmin protein levels were not 
significantly altered in the AD brain [167]. Nevertheless, Aβ40 aggregate-induced 
neurotoxicity in primary rat cortical neuronal cultures can be fully mitigated by plasmin 
treatment [168]. One group reported that plasmin also increases the processing of human 
APP preferentially at the α cleavage site and efficiently degrades secreted APP fragments 
[169, 170]. Plasmin is closely associated with cholesterol-enriched membrane microdomains 
called lipid rafts, a preferred site of Aβ generation [171]. It is therefore likely to reduce Aβ 
levels at a site close to production.
6.6. Matrix Metalloproteinases (MMPs)
MMPs belong to the family of zinc-dependent enzymes that are synthesized as prepro-
peptides and are released into the extracellular space as pro-MMPs. Activation of pro-MMPs 
involves an initial cleavage of part of the propeptide by a tissue, plasma or bacterial 
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proteinase followed by the final removal of the propeptide by an MMP intermediate or 
another MMP [172, 173]. After activation, MMPs are able to breakdown extracellular matrix 
and are essential for embryonic development, tissue resorption and remodeling. 
Inappropriate expression of MMPs has been associated with a wide range of disorders 
including cardiovascular diseases [173], asthma [174], and multiple sclerosis [175].
An increase of both MMP expression and CSF levels of the major endogenous inhibitor of 
MMPs, tissue inhibitor of metalloproteinases (TIMP), have been documented in AD patients 
[176, 177]. In contrast, other studies have compared AD to other neurodegenerative 
disorders and have found either no change or reduced levels of MMPs and TIMPs within the 
CSF [178, 179]. One study reported an increase in MMP activity in the hippocampus of 
post-mortem AD patients [180]. Of the MMPs, specifically MMP-2, MMP-3, and MMP-9 
have been implicated in Aβ degradation. Although MMP-2, MMP-3, and MMP-9 levels are 
not related to Aβ levels in the frontal cortex of AD [181], various studies have suggested that 
these three MMPs are stimulated by Aβ [177, 182–184].
MMP-2 cleavage of Aβ40 and Aβ42 has been mapped to the Lys16-Leu17, Leu34-Met35, and 
Met35-Val36 peptide bonds to generate Aβ fragments that have been detected in vivo [185]. 
In addition to MMP-2’s ability to degrade exogenous Aβ40 and Aβ42, MMP-2 activator, 
membrane type 1 MMP, it has been reported to degrade fibrillar amyloid plaques extracted 
from APP transgenic mice [186]. MMP-3’s ability to degrade Aβ directly is unclear; 
however, MMP-3 appears able to degrade Aβ indirectly by activating other MMPs, like 
MMP-9 [182, 187]. It has been demonstrated that MMP-9 cleaves soluble Aβ primarily 
between Leu34-Met35 and secondarily at the Lys15-leu17, Ala30-Ile31, and Gly37-Gly38, sites 
that are considered to be important for β-sheet formation [187]. When compared to other 
degrading proteases, such as ECE, IDE, and NEP, MMP-9 was found to be unique in its 
ability to degrade Aβ fibrils in vitro and within compact plaques in situ, liberating Aβ 
fragments 1–20 and 1–30 by cleaving sites within the hairpin loop formation of the β-sheet 
structure [186, 188]. Nevertheless, more studies are required to confirm and understand the 
role of this nearly ubiquitous protease family.
CONCLUSION
Typical late onset AD has a prolonged course of development and amyloid deposits 
accumulate for numerous years before causing dementia. For patients with FAD carrying the 
highly penetrant dominantly inherited mutations, Aβ production begins 30–60 years prior to 
the onset of dementia [189–194]. Furthermore, amyloid appears to even deposit twenty or 
more years before the onset of dementia [189–194]. In this regard, it is of interest that using 
noninvasive amyloid plaque and NFT imaging technologies combined with family history 
and APOE genotypes, one can identify individuals at risk for developing AD. This is 
important for recruitment of subjects for clinical trials and for individual planning to 
confront this devastating disease. A number of clinical trials strongly suggest that late 
treatment of AD to eliminate Aβ is ineffective in restoring patients after dementia is 
detected, indicating that blocking the initial step to the complex process leading to AD late 
during the disease course is insufficient when the nervous system has already undergone 
degeneration. Furthermore, Aβ-induced initiation of MAPT phosphorylation and 
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neuroinflammation over a decade prior to the development of dementia likely instigates self-
sustaining cycles that drives ‘clinically silent’ disease towards the development of clinically 
observable MCI and AD, and, once initiated, such cycles will be little impacted by later 
treatments focused on Aβ removal [195]. Despite this, a number of opportunities for 
prevention or early preclinical intervention remain feasible [3]. As discussed earlier, the 
ApoE genotype and molecular imaging of SP and NFT has converged to identify individuals 
at high risk of developing AD, making it particularly important to identify paradigms for AD 
prevention. It has been reported that that AD patients suffer from poor Aβ clearance [126], 
suggesting that reducing Aβ production early in the development of pathology may be 
protective. The best-developed paradigm for potentially reducing Aβ has been the 
development and use of γ-secretase inhibitors. However, others and we have previously 
proposed that, contrary to one of the predictions of the amyloid hypothesis, AD may be 
caused by γ-secretase inhibition [23, 24, 196]. Nevertheless, our recent findings that partial 
γ-secretase inhibition paradoxically increases Aβ by a mechanism that bypassed Aβ 
degradation reconciles the two theories [45]. This study also indicates that ECE is a major 
Aβ-degrading pathway, but there are additional unidentified Aβ degrading pathways in the 
cell that need to be characterized. In addition, there are proteins other than Aβ and MAPT 
that accumulate in the AD brain indicating that there is a more generalized failure of protein 
homeostasis that needs to be addressed [46]. The major constitutive protein degradation 
systems include the lysosomal pathway, the proteasome and membrane-associated neutral 
endopeptidases such as matrix metalloproteases. Intramembrane proteolysis by γ-secretase is 
a recent addition to this rather small list of pathways. Efficient degradation of Aβ is critical 
to maintain low levels and to avoid accumulation of homo-polymers that form 
spontaneously. Yet the pathways for Aβ degradation have not been systematically evaluated. 
This review summarizes the current state of knowledge on Aβ degradation and highlights the 
key lacunae that need to be filled in order to understand the role of this pathway in 
preventing SP biogenesis.
The major pathways demonstrated to be involved in degrading Aβ are ECE, NEP, IDE, 
Cathepsin B, plasmin and MMP. ECE and NEP are membrane proteases that are tissue and 
brain region specific in their relative distribution. IDE is a cytosolic enzyme but is secreted 
by an unknown mechanism and is a potent Aβ degrading enzyme. Cathepsin B is an 
endosomal-lysosomal protease, which has been identified as a β-secretase that can generate 
Aβ, but knockout mouse studies suggest that it is an Aβ-degrading enzyme. Although 
convincing genetic variant association has not been demonstrated in humans for these 
activities with the exception of IDE, mice lacking these enzymes show increases in amyloid 
accumulation. ECE is the only enzyme whose inhibition acutely increases Aβ production in 
cell cultures suggesting that the Aβ degradation is actually coupled to production in the 
endosome. However, we have recently published data showing that γ-secretase inhibition 
allows Aβ to bypass degradation by multiple activities in the endosomal pathway [45]. Since 
inhibition of lysosomal proteolysis using known inhibitors does not increase yield of Aβ, we 
propose that there are novel lysosomal proteases that degrade Aβ that need to be identified. 
Understanding the clearance pathways will allow us to determine whether and how this 
mechanism is impaired in AD. Moreover, the degradation pathways may offer targets that 
can be stimulated to prevent amyloidosis. This type of approach may have advantages over 
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inhibiting critical multifunctional enzymes in the Aβ biogenesis pathways. Therefore, 
additional research is needed on Aβ degrading enzymes as well as on the earliest events in 
amyloid accumulation in addition to identifying the steps that lead from Aβ to 
neurodegeneration.
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LIST OF ABBREVIATIONS
Aβ Amyloid-β proteins
Aβ40 Aβ of 40 aa
Aβ42 Aβ of 42 aa
ACE Angiotensin Converting Enzyme
AD Alzheimer’s disease
ADAM 10 Adamalysin10
ApoE Apolipoprotein E
ApoE-ε4 ApoE ε4 allele
APP Aβ precursor protein
BACE1 β-site APP cleaving enzyme
CERAD Consortium to Establish a Registry for Alzheimer’s disease
CTFβ APP Carboxy terminal fragment of 99 aa
CTFa APP Carboxy terminal fragment of 83 aa
DCP-1 Dipeptidyl carboxypeptidase-1
ECE Endothelin-converting Enzyme
ER Endoplasmic reticulum
ERAD ER-associated degradation
FAD Familial AD
HD Huntington’s disease
IDE Insulin-degrading Enzyme
MAPT Microtubule-associated protein tau
MMPs Matrix metalloproteinases
NEP Neprilysin
NFT Neurofibrillary tangles
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PD Parkinson’s disease
PS1 Presenilin-1
PS2 Presenilin-2
SP Senile plaques
TIMP Tissue inhibitor of metalloproteinases
UPS Ubiquitin-Proteasome System
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Fig. 1. Key APP processing pathways
The neuronal form of APP is a type-1 integral-membrane glycoprotein of 695 aa with a large 
ectodomain a single transmembrane domain and a short intracellular domain (Blue box). A 
group of metalloproteases named α-secretase cleave APP inside the Aβ sequence (violet 
triangle) between residues 16 and 17 to produce a secreted fragment of 612 aa, sAPPα, and 
a cellular fragment of 83 aa - CTFα. This is the major pathway and accounts for 80–90% of 
APP turnover. In the amyloidogenic pathway, BACE1 (β) cleaves APP to the secreted 
fragment, sAPPβ (red diamond), of 596 aa and membrane-bound fragment CTFβ of 99 aa. 
Which in turn is processed to Aβ by γ-secretase. Aβ is degraded and cleared by multiple 
known and unknown pathways as shown.
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Fig. 2. Model showing the cell biology of Aβ production and degradation
APP is synthesized in the ER and gets transported to the Golgi apparatus where it is 
packaged to vesicles (orange circles) for delivery to the cell surface (Step 1.). APP that does 
not get processed by the α-secretase in the secretary pathway is internalized into endosomes 
(Large blue circles), which are acidic compartments (Steps 2 and 3). BACE1 cleaves APP in 
the endosome to generate CTFβ, which is then processed to Aβ by γ-secretase within the 
endosome (Step 4). In neurons, a large fraction of the Aβ generated in this compartment is 
degraded by ECE and unknown proteases (Step 5). Aβ that escapes this pathway may be 
transported to the lysosome and degraded (Step 6). Alternatively, Aβ containing recycling 
vesicles (small blue circles) can be recycled to the cell surface either via the Golgi apparatus 
(Steps 7 and 8)or directly from the endosome to the cell surface (Step 9). Aβ may be 
released from recycling vesicles to the UPS for degradation (Step 10) or get degraded at the 
cell surface by other known pathways such as NEP, IDE, MMP-9 or by other unidentified 
pathways. The Aβ that escapes degradation may be drained into the cerebrospinal fluid or 
cleared into the lymphatic or vascular circulation. Failure of all these redundant turnover 
mechanisms will lead to accumulation and aggregation of Aβ into SP and as CVAP.
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Fig. 3. Sequence variants of endothelin converting enzyme
ECE-1 is a type-II membrane protein with a variable N-terminal intracellular (IC) domain, 
and conserved transmembrane (TMD) and extracellular (Lumen) domains [153]. Through 
multiple alternate promoters, at least four isoforms of ECE-1 have been identified, each with 
unique intracellular domains that determine subcellular localization and tissue distribution, 
Isoforms 1a and 1c are primarily localized in the plasma membrane, whereas isoform 1b and 
1d are predominantly located in late endosomes/multivesicular bodies and recycling 
endosomes, respectively [70, 119, 154].
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Table 1
List of known Aβ degrading enzymes with their major substrates.
Enzyme Name Substrate
Levels/Activity in 
AD Brain vs. 
Control
Metal - Binding References
Neprilysin
Aβ, Bradykinin, Substance P, 
Angiotensin-I, Angiotensin-II, 
Endothelin-1, Kinins, 
Adrenomedullin, Opioid 
peptides, enkephalin, gastrin
Increased
Reduced Zinc [150, 149]
Endothelin-converting enzymes (ECE)
Aβ, Endothelin, substance P, 
bradykinin, angiotensin I, 
neurotensin, somatostatin
ECE-1 (no change), 
ECE-2 (reduced) Zinc [158, 157]
Insulin degrading enzyme (IDE)
Aβ, Insulin, atrial natriuretic 
peptide, insulin-like growth 
factor II, transforming growth 
factor-α, β-endorphin, amylin, 
glucagon
Increased
Reduced Zinc [134, 139, 149]
Angiontensin-converting enzyme (ACE) Aβ, Angiotensin I, Bradykinin Increase Zinc [163–165]
Matrix metalloproteinases (MMP) - 
primarily MMP-2, MMP-3 and MMP-9 Aβ, collagen proteins, gelatin Increase activity Zinc and calcium [180]
Cathepsin B Aβ, APP Unknown Thiol [121, 122, 124]
Plasmin
Aβ, Fibrin, collagenases, 
fibronectin, thrombospondin, 
laminin, von willebrand factor
Reduced activity [170]
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